Skip to main content
Chun-ying Sheng on Muck Rack

Chun-ying Sheng

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chun-ying

Contact Chun-ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Phase II study of SHR-A1921, a TROP2-targeted antibody–drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma

|
By Guang-Liang Chen, Yanjing Guo, Ya’nan Yang, Youzhou Sang, Si Sun, Xin Zhe Liu, Xin Zhou, Jianfei Wang, Rongliang Shi, Yu Wang, Qinghai Ji, Dongmei Ji, Chun-ying Sheng, Xiayun He
| Nature Verified
Abstract Advanced salivary gland carcinoma (SGC) lacking both human epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) expression has limited treatment options. In this single-center, phase II trial, patients with recurrent/metastatic HER2-negative/AR-negative SGC received SHR-A1921, a TROP-2-directed antibody-drug conjugate, every 3 weeks until disease progression or unacceptable toxicity.
Open in Who Shared Issue with article?
See all 1 articles